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A B S T R A C T
Background
“Foot drop” or “Floppy foot drop” is the term commonly used to describe weakness or contracture of the muscles around the ankle
joint. It may arise from many neuromuscular diseases.
Objectives
To conduct a systematic review of randomised trials for the treatment of foot drop resulting from neuromuscular disease.
Search methods
In this update, we searched the Cochrane Neuromuscular Disease Group Trials Register (April 2009), MEDLINE (January 1966 to
April 24 2009), EMBASE January 1980 to April 24 2009), CINAHL (January 1982 to May 6 2009), AMED (January 1985 to April
24 2009), the British Nursing Index (January 1985 to January 2008) and Royal College of Nursing Journal of Databases (January 1985
to January 2008).
Selection criteria
Randomised and quasi-randomised trials of physical, orthotic and surgical treatments for foot drop resulting from lower motor neuron
or muscle disease and related contractures were included. People with primary joint disease were excluded. Interventions included a
’wait and see’ approach, physiotherapy, orthoses, surgery and pharmacological therapy. The primary outcome measure was quantified
ability to walk whilst secondary outcome measures included range of movement, dorsiflexor torque and strength, measures of activity
and participation, quality of life and adverse effects.
Data collection and analysis
Methodological quality was evaluated by two authors using the van Tulder criteria. Four studies with a total of n = 152 participants
were included in the update to the original review. Heterogeneity of the studies precluded pooling the data.
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Main results
Early surgery did not significantly affect walking speed in a trial including 20 children with Duchenne muscular dystrophy. Both groups
deteriorated during the 12 months follow-up. After one year, the mean difference (MD) of the 28 feet walking time was 0.00 seconds
(95% confidence interval (CI) -0.83 to 0.83) and the MD of the 150 feet walking time was -2.88 seconds, favouring the control group
(95% CI -8.18 to 2.42). Night splinting of the ankle did not significantly affect muscle force or range of movement about the ankle
in a trial of 26 participants with Charcot-Marie-Tooth disease. Improvements were observed in both the splinting and control groups.
In a trial of 26 participants with Charcot-Marie-Tooth disease and 28 participants with myotonic dystrophy, 24 weeks of strength
training significantly improved six-metre timed walk in the Charcot-Marie-Tooth group compared to the control group (MD 0.70
seconds, favouring strength training, 95% CI 0.23 to 1.17), but not in the myotonic dystrophy group (MD -0.20 seconds, favouring
the control group, 95% CI -0.79 to 0.39). No significant differences were observed for the 50 metre timed walk in the Charcot-Marie-
Tooth disease group (MD 1.90 seconds, favouring the training group, 95% CI -0.29 to 4.09) or the myotonic dystrophy group (MD
-0.80 seconds, favouring the control group, 95% CI -5.29 to 3.69). In a trial of 65 participants with facioscapulohumeral muscular
dystrophy, 26 weeks of strength training did not significantly affect ankle strength. After one year, the mean difference in maximum
voluntary isometric contraction was -0.43 kg, favouring the control group (95%CI -2.49 to 1.63) and the mean difference in dynamic
strength was 0.44 kg, favouring the training group (95%CI -0.89 to 1.77).
Authors’ conclusions
Only one study, involving people with Charcot-Marie-Tooth disease, demonstrated a statistically significant positive effect of strength
training. No effect of strength training was found in people with eithermyotonic dystrophy or facioscapulohumeral muscular dystrophy.
Surgery had no significant effect in children with Duchenne muscular dystrophy and night splinting of the ankle had no significant
effect in people with Charcot-Marie-Tooth disease. More evidence generated by methodologically sound trials is required.
P L A I N L A N G U A G E S U M M A R Y
Rehabilitation for foot drop (weakness or muscle shortening (contracture) at the ankle joint)
Foot drop is the term commonly used to describe weakness or contracture of the muscles at the ankle joint. It may arise from many
neuromuscular diseases. Interventions might include a ’wait and see’ approach, physiotherapy, orthotics (appliances), surgery or drug
therapy. The review update identified four randomised controlled trials that met the criteria for inclusion, including 152 participants
in total. In one trial strength training had a significant beneficial effect on walking ability in people with Charcot-Marie-Tooth disease
(hereditary motor and sensory neuropathy), but no significant effect on walking ability in people with myotonic dystrophy. In another
study strength training had no significant effect on ankle strength in people with facioscapulohumeral muscular dystrophy. Night
splinting of the ankle had no significant effect on flexibility or muscle strength around the ankle in people with Charcot-Marie-Tooth
disease, and surgery on the Achilles tendon in boys with Duchenne muscular dystrophy had no significant effect on their walking
ability. Further randomised controlled trials are needed.
B A C K G R O U N D
This Cochrane review investigated the problem of weakness and
contracture of themuscles around the ankle joint, which arise from
neuromuscular diseases affecting lower motor neurons (LMN) or
muscle. This condition is commonly called foot drop or ’floppy
foot drop’ (Donaghy 2001). Foot drop can have a profound effect
on gait. In moderate cases, the front of the foot drops to the
floor after heel strike, preventing the stride leg from swinging
through, while in severe cases toe strike may precede heel strike
and the toe may catch the ground during swing-through of the leg,
which may lead to tripping or falling. Using the terminology of
the International Classification of Function, Disability andHealth
(WHO2001), foot drop is thus an ’Impairment of Body Structure’
that may markedly influence the ’Activities’ and ’Participation’ of
the affected individual.
The major cause of foot drop is weakness of the muscles of ankle
dorsiflexion, primarily tibialis anterior, but also weakness of the
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long extensors of the toes (extensor hallucis longus and extensor
digitorum longus). A significant, secondary effect of this weak-
ness is shortening and contracture of the Achilles tendon, which
is formed by the merging of the tendinous portions of the major
muscles of plantar flexion, the gastrocnemius and soleus. How-
ever, the ankle is a complex bipartite joint, able to move in four
directions: dorsiflexion, plantar flexion, eversion and inversion.
Many of the conditions, which cause weakness of the dorsiflexors,
also affect the muscles of eversion (peroneus tertius and peroneus
longus) and inversion (tibialis posterior). The foot drop syndrome
therefore often incorporates weakness of these muscles, and asso-
ciated contracture of their antagonist muscle tendons. The exact
contribution may differ between conditions.
This review, therefore, has greater clinical relevance if the term
Achilles tendon is seen as convenient shorthand for all the ten-
dons acting around the ankle joint, which may be involved when
foot drop occurs. We included research that describes weakness
of the other muscles that move the ankle, not only isolated in-
volvement of the dorsiflexion agonists, as long as the lower motor
neuron was primarily affected. This review specifically excluded
ankle weakness secondary to upper motor neuron lesions and soft
tissue contractures associated with non-neurological disease, such
as arthritis or burns.
Aetiology of foot drop and contracture
Floppy foot drop can result from damage to any part of the lower
motor neuron between the lumbosacral spine and the muscles of
ankle dorsiflexion. Classified anatomically, a non-exhaustive list
of the common causes would include:
• Anterior horn cell of the spinal cord (e.g. poliomyelitis and
motor neuron disease).
• Motor nerve root (e.g. cauda equina lesions and
involvement of the lumbosacral nerve roots as they exit from the
spine, usually associated with intervertebral disc prolapse).
• Peripheral motor nerve as part of a diffuse peripheral
neuropathy (including Guillain-Barré syndrome, chronic
inflammatory demyelinating polyneuropathy).
• Hereditary motor and sensory neuropathy (e.g. Charcot-
Marie-Tooth disease).
• Involvement of specific peripheral nerves derived from the
sciatic plexus:
(a) the sciatic nerve as it passes from the pelvis through the sciatic
notch, past the hip joint and into the leg (e.g. with pelvic fractures,
buttock injections, and following pelvic surgery and hip replace-
ment).
(b) the peroneal nerve, which supplies all the evertors and dorsi-
flexors of the ankle (often as a result of lower limb fractures where
the nerve traverses the fibular head).
• Primary muscle disease (e.g. muscular dystrophy, including
Duchenne, Becker, facioscapuloperoneal and Emery-Dreifuss
dystrophies).
Incidence and prevalence of foot drop
The incidence and prevalence is hard to establish. Geboers
(Geboers 2001a) suggested one new case per 6000 people each
year, based on referrals of newly affected patients to a Neurology
and Rehabilitation Service in Heerlen, Netherlands, serving an es-
timated population of 300,000. As the majority of the cases had
either peroneal nerve palsy or prolapsed discs, and the referral rate
in the area was not known, this may well have been an underesti-
mate. Any neurological rehabilitation unit sees a significant num-
ber of affected patients annually.
Treatment modalities
Despite the frequency of foot drop, and the serious effect that it has
on gait and general function, the literature provides little direction
as to its treatment. Recent comprehensive textbooks on neurology
and neurorehabilitation tend to address the matter only briefly,
offering various therapeutic options in a non-critical way; for ex-
ample ’it is important to prevent contracture of the Achilles ten-
don, and the foot should be splinted in dorsiflexion day and night,
and the ankle moved through its full range passively’ (Donaghy
2001).
Several therapeutic approaches known to be used in practice in-
clude ’wait and see’ (i.e. no intervention), physiotherapy, surgery
and drug treatment. The authors could not locate any recent, for-
mal reviews in the published literature that critically compare these
approaches. This review aims to fill the gap as a basis for making
clinical decisions, identifying the need for trials and maintaining
an up to date record of such research in the future.
O B J E C T I V E S
The objective was to systematically review all randomised and
quasi-randomised trials of the treatment and rehabilitation of foot
drop resulting from lowermotor neuron or muscle disease, includ-
ing the prevention and treatment of contractures that develop in
association with such foot drop.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
We included all randomised controlled trials (RCTs) and quasi-
randomised trials of physical, orthotic and surgical approaches in
the treatment of lower motor neuron foot drop, and the preven-
tion and treatment of Achilles tendon contracture, and other soft
tissue contractures that develop in association with such foot drop.
Quasi-randomised trials are those trials in which treatment alloca-
tion was intended to be random, but might have been biased (e.g.
alternate allocation).
Types of participants
We included studies pertaining to participants of all ages whowere
described as at having:
• lower motor neuron or ’floppy’ foot drop, whether the
diagnosis was made clinically or through nerve conduction
studies and EMG; and/or
• contractures of the Achilles tendon (or other associated
tendons) that had developed secondary to the foot drop, and
which affected the range of motion of the ankle.
We specifically excluded participants with primary joint or soft
tissue problems (e.g. arthritis or burns).
Types of interventions
We included all therapeutic approaches that are known to be used
in practice, whether used alone or within the context of a multi-
disciplinary rehabilitation programme, such as:
• A non-interventionist approach based on the expectation
that recovery will occur equally well without treatment or that
the deficit does not warrant treatment, at least at present.
• Physiotherapy, which may have several components:
(a) maintenance of passive range of motion;
(b) attempts to improve active muscle movement and/or strength
through isotonic or isometric exercise (Germain 1995; Rozier
1979);
(c) attempts to improve active muscle movement and/or strength
through electrical nerve stimulation, often referred to as Func-
tional Electrical Stimulation. Functional Electronic Stimulation
is also an “orthotic” intervention in that the stimulation of dor-
siflexors during heel strike can cause the muscle to contract and
dorsiflex the foot, whether or not it has any lasting effect upon the
muscle or nerve.
• Orthoses, used to splint the joint in a functional position.
At rest, these prevent the foot falling into a position of forced
plantar flexion, which could lead to the development of a
contracture and have a major effect on gait. The risk of tripping
while walking is also minimised, with a positive effect on patient
safety. However, some debate has developed as to whether
orthotics will enhance recovery of the paretic muscle by
facilitating walking, or retard recovery through immobilisation
and disuse atrophy (Geboers 2001a; Geboers 2001b; Geboers
2002; Tropp 1995). As noted above, Functional Electronic
Stimulation can also be considered to be an orthotic intervention.
• Surgery of various types, including tendon lengthening
procedures and transfers (Wiesseman 1981), and other
orthopaedic interventions such as subtalar arthrodesis (Jaivin
1992). Surgical management of the primary cause, such as
lumbar disc surgery for prolapse or decompression of the
peroneal nerve, is outside the scope of this review.
• Pharmacological therapy was included as some modalities
(such as nerve growth factor administration) may well become
important in the future. However where this has formed the
topic for another Cochrane review, the authors will defer to its
content, rather than reviewing the topic independently.
Types of outcome measures
The primary outcome measure was walking ability, using a vali-
dated objective test, limited either by distance (e.g. the 10-metre
walk, with and without stairs) or time (e.g. the six-minute en-
durance test).
Secondary outcomes included:
• Active and passive range of motion of the ankle (measured
using a goniometer or inclinometer).
• Dorsiflexor torque and strength (measured using a
dynamometer, 1 Repetition maximum, Medical Research
Council scale).
• ’Activities’ and “participation” (WHO 2001) measured
with validated tools, and orientated to either Basic Activities of
Daily Living (e.g. the Barthel Activities of Daily Living Index),
or Instrumental Activities of Daily Living (e.g. Nottingham
Extended Activities of Daily Living scale).
• Quality of life (including measures of pain and fatigue).
• Adverse effects attributable to the intervention, e.g.
ulceration preventing use of an orthodox device, and falls.
Search methods for identification of studies
Electronic searches
For this update, we searched theCochraneNeuromuscularDisease
Group Trials register (searched April 2009), MEDLINE (from
January 1966 to April 24 2009), EMBASE (from January 1980
to April 24 2009), CINAHL (from January 1982 to May 6 2009)
and AMED (from January 1985 to April 24 2009). The British
Nursing Index and Royal College of Nursing Journal of Databases
was also studied (from January 1985 to January 2008).
The following search terms were used:
• foot drop OR floppy foot drop
• ankle contracture OR Achilles tendon contracture OR
shortening
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• lower motor neuron lesions
• exercise OR physiotherapy
• orthotics
• nerve stimulation
• surgery
The search strategies have been modified for this update to iden-
tify randomised controlled trials that were not being identified
in the original search. See Appendix 1, Appendix 2, Appendix 3,
Appendix 4 and Appendix 5 for search strategies.
Searching other resources
In the original protocol we proposed to contact authors but we
were only able to contact Dr E van der Kooi and Dr E Lindeman.
Data collection and analysis
The titles and abstracts were screened and the full texts of poten-
tially relevant articles were obtained. Three authors (NB, TH, PD)
independently reviewed these articles and decided on their inclu-
sion. No disagreement between authors was encountered. Two of
the authors (NB, TH) independently assessed the methodological
quality of the studies using a standardised grading system. Any
uncertainties were discussed and mutual agreement was formed.
Selection of studies
Studies were included if:
• they were randomised or quasi-randomised
• over 60% of participants included initially had follow up
data
• the control group did not exercise the leg systematically
Studies were excluded if:
• the study protocol was not adhered to
• the groups varied greatly at entry (baseline) and there was
no statistical adjustment for this
Assessment of methodological quality
Many previous Cochrane reviews have based their assessments on
the three essential criteria described by Jadad et al. (Jadad 1996)
including method of treatment allocation, whether trials have en-
sured an intention-to-treat analysis and attempted concealment of
allocation. These criteria were developed for interventional trials
of drug therapy, but are less easy to apply to trials of rehabilita-
tion where, as discussed by Turner-Stokes (Turner-Stokes 2005),
blinding of subjects and therapists is rarely possible as they are
aware of when treatment is being implemented and received. An
alternative checklist, the van Tulder scale was therefore employed
(van Tulder 1997). The scale includes the three Jadad criteria, but
adds further criteria to reach a total of 19 (11 criteria for inter-
nal validity, 6 descriptive criteria and 2 statistical criteria) (Table
1). This approach was used for methodological evaluation in this
review, and on this basis an RCT was considered to be of high
methodological quality if there were positive scores on at least six
out of eleven internal validity items, at least three out of six de-
scriptive items and at least one out of two statistical items.
Blinding
In the rehabilitation context, it is seldom possible to blind either
participants or therapists to the therapeutic intervention.However
it is usually possible to blind the assessor.
Concealment of treatment allocation
Examples of ’adequate procedures’ for treatment allocation con-
cealment are:
• assignment of treatment at random by an independent
person not responsible for determining the eligibility of the
participants
• a centralised randomisation scheme, e.g. a computer system
providing allocations in a locked, unreadable file that could be
assessed only after inputting the characteristics of an enrolled
participant
• numbered or coded containers, or sequentially numbered,
sealed, opaque envelopes
If the concealment of treatment allocation was described only as
random or randomised, it was considered unclear.
Adverse effects
Adverse effects of rehabilitation are potentially possible, but are
considered infrequent by clinicians. The absence of adverse effects
is therefore seldom specifically recorded. Nonetheless we looked
for recording of adverse events.
Analysis and data synthesis
Meta-analysis can be undertaken only if the study populations,
interventions, outcomes and study designs are agreed to be suf-
ficiently consistent to allow pooling of data. There was, as will
be seen, too much clinical heterogeneity among the studies with
regard to participants (diagnosis and severity of disease), inter-
vention (duration, frequency and setting) and outcome measures
(diversity of assessment tools) to make such analyses possible in
this review. To facilitate interpretation of results, mean difference
is scored positive if the outcome favours the intervention group as
opposed to the control group.
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R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Included studies
The total number of references yielded by the search update (orig-
inal search) was as follows: NMD Group specialised register 17
(17) references, AMED 157 (15) references, CINAHL 288 (52)
references, EMBASE 290 (44) references,MEDLINE 56 (17) ref-
erences. The number studied in full text was 23, compared to 12
in the original review. A PhD thesis reporting a study published
in two articles was not reviewed separately. There was no disagree-
ment between the two authors in terms of the inclusion and exclu-
sion of studies. Four studies were included (reported in eight pub-
lications). One study included boys with Duchenne muscular dys-
trophy, one included adults with facioscapulohumeral muscular
dystrophy, one included participants with Charcot-Marie-Tooth
disease and one included participants with either myotonic dys-
trophy or Charcot-Marie-Tooth disease (Hereditary Motor and
Sensory Neuropathy). These studies have been discussed below
under their respective neuromuscular disease headings.
Duchenne muscular dystrophy
Surgical intervention
Manzur 1992 studied the effects of surgical intervention in boys
with Duchenne muscular dystrophy. Participants, aged four to six
years, were randomised to either conservative treatment or surgi-
cal intervention. Surgery used Rideau’s approach (Rideau 1986).
This consists of open release at the hip of the sartorius muscle, the
superficial head of the rectus femoris muscle and tensor fasciae lati.
The Achilles tendon is lengthened and hamstring tendons released
if there are knee flexion contractures. Participants were transferred
to hospital after three days where they were mobilised by physio-
therapy between the third and sixth day after surgery. They were
discharged home four to six days following surgery, walking with-
out orthotic support, and without routine passive stretching or
physiotherapy. The control group continued with regular passive
stretching of the Achilles tendon, iliotibial bands and hip flexors,
performed daily by the parents after demonstration by the phys-
iotherapist. All boys were assessed at three-month intervals in the
first year, and twice annually thereafter.
Outcome evaluation was based on walking time over 28 and 150
feet, muscle strength (rated using the Medical Research Coun-
cil Scale (MRC 1943), myometry of five muscle groups in the
legs and two in the arms, the timing of Gowers’ manoeuvre, mo-
tor ability (based on 20 activities), measurement of contractures,
gait analysis, ultrasound of the quadriceps femoris muscle. Needle
muscle biopsy of the vastus lateralis muscle was carried out before
and after operation. Clinical photographs and video recordings of
movement quality were also taken.
Twenty-eight boys were assessed for recruitment. Eight were re-
jected. Three were too weak, two were unable to co-operate with
assessments, the parents of two boys refused consent and one had
experienced complications during previous surgery. Twenty boys
were therefore randomised into the two groups defined above (n =
10 in each group). Surgery was tolerated well in the surgical group
with all participants discharged within a week of surgery. The mo-
tor ability score and Medical Research Council Scale scores were
similar between the two groups at baseline. All participants were
followed up for a minimum of one year, the time used for follow-
up analysis. Four of the ten operated boys showed initial improve-
ment in qualitative gait analysis. This improvement was defined
by the authors as “particularly related to improved heel strike” and
was apparently “still noticeable up to a year after surgery”. Formal
gait analysis revealed no significant difference between the two
groups at one year on any of the six parameters studied (step and
stride length, swing phase duration, double support time, cadence
and velocity). No difference between groups was found in Med-
ical Research Council Scale score, myometry or Gower’s times at
follow-up.
Achilles tendon contractures were all severe in the surgical group
and were reduced by surgery from a mean of 26° to 16° at three
months. However, two of the ten boys developed contractures
again within one year of surgery. Iliotibial band contractures were
reduced from a mean of 6º to 1º at one-year follow-up.
Ultrasound scanning of the muscles which was found to be ab-
normal in all participants before surgery, revealed no significant
change or differences between groups at one year follow-up.
At two years, five boys in the control group and six in the surgical
groupwere reassessed. Recurrences of Achilles tendon contractures
were noted in five of the six operated boys on at least one side.
One boy lost independent ambulation by 2.5 years after surgery.
The authors concluded that “there was no measurable difference
betweenour surgical and conservative groups andour study has not
shown any benefit of early surgery in relation to muscle strength
and function”. They noted that contractures could be reduced in
the short-term but recurred in at least seven of the 10 boys within
one to two years of surgery.
A long-term follow up of the same group of 20 boys a mean of
nine years after surgery was published as an abstract for the Fourth
International Congress of the World Muscular Dystrophy Soci-
ety in 1999, but the number of participants at follow up was not
specified. The follow-up revealed recurrence of contractures in all
boys in the surgical group and authors concluded that early limb
surgery demonstrated no functional benefit. The Rideau opera-
tion was not therefore recommended as routine treatment for this
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condition.
Facioscapulohumeral muscular dystrophy
Exercise and strength training
Moderate-resistance strength training was studied in patients with
facioscapulohumeral muscular dystrophy by van der Kooi 2007;
van der Kooi 2004. Sixty-five of the 97 participants that were ran-
domly assigned either to a “training” (T) or “non training” (NT)
group completed the study. The training group underwent mod-
erate, progressive strength training focusing on elbow flexors and
ankle dorsiflexors. Training consisted of predominantly dynamic
exercises carried out at home three times a week for 26 weeks. After
26 weeks the training and non-training groups were secondarily
randomised to either albuterol (A) or placebo (P). Assessments
took place at 0, 26 and 56 weeks for muscle strength (isometric,
sustained and dynamic). Muscle mass was also estimated using
computerised tomography. Questionnaires on self-reported pain,
fatigue, health-related functional status and psychological distress
were collected from participants at 0 and 52 weeks.
All strength parameters of the ankle dorsiflexors decreased signifi-
cantly between 0 and 52weeks in each of the four treatment groups
(T+P, T+A, NT+P, NT+A). These results were not influenced by
training or the use of albuterol. Training of elbow flexors did not
result in any significant on isometric or sustained muscle strength,
however dynamic elbow strength improved significantly. Isomet-
ric elbow flexor strength increased significantly in the Albuterol
group compared to the placebo group. The difference in mean
change from baseline between the albuterol and control groups
for sustained and dynamic strength of the elbow flexors was not
significant. The authors concluded that strength training and al-
buterol appear safe interventions with limited muscle strengthen-
ing effects in fascioscapulohumeral muscular dystrophy.
Strength training and albuterol failed to have a significant effect
on pain, fatigue, health-related functional status and psychological
distress. The authors concluded that neither strength training nor
albuterol have a clear positive or negative effect on these outcomes.
Myotonic dystrophy
Exercise and strength training
Lindeman 1995 studied strength training in participants with my-
otonic dystrophy. Patients living within 100 km of Maastricht be-
tween the age of 16 and 60 years were recruited and subjected to
a “qualification period” to establish their suitability for the trial,
and provide themwith the information necessary for them to con-
sent. Participants were excluded based on any contraindications to
muscle strengthening exercises or other unrelated disabling condi-
tions that could influence the scoring. Thirty-six participants were
individually matched on the basis of muscle strength and perfor-
mance on a stair-climbing test before being randomly assigned to a
training or control group. The treatment group carried out home
based knee extension and flexion, and hip extension and abduc-
tion weight exercises three times a week for 24 weeks, completing
a training diary over the course of the programme. Training was
progressive over the course of the 24-week programme. Over the
first eight weeks participants carried out three sets of 25 repetitions
at 60% of one maximum repetition (1RM). From the ninth to the
sixteenth week, intensity was increased to three sets of fifteen rep-
etitions at 70 % of 1RM, and during the final eight week period,
the intensity progressed further to three sets of ten repetitions at
80 % of 1RM. Outcome assessments were carried out after eight,
sixteen and 24 weeks by an observer blinded to treatment alloca-
tion. Outcome measures used included isokinetic and isometric
muscle strength and endurance (using a CYBEX Dynamometer),
and functional performance based on stair climbing, rising from
a chair or from supine, and walking 6 and 50 metres. In addition
participants completed the Western Ontario & MacMaster Uni-
versity Osteoarthritis Index (WOMAC) and the Sickness Impact
Profile (SIP). Participants also scored their difficulty in perform-
ing life activities on a Visual Analogue Scale. Finally they were
asked to identify the “disease related problems they faced in daily
life” using a questionnaire adapted from the “Problem Elicitation
Technique” (PET).
Compliance with therapy was high and a low drop out rate was
observed. Of the 36 participants randomised, 28 were analysed.
With respect to physical functional abilities, there was no signifi-
cant change in stair climbing, rising from a chair or from supine
position, or walking six or 50 metres. Based on theWOMAC, sta-
tistically significant improvement was found in standing, getting
into and out of a car and putting on socks.
Most of the hindrances reported in the Problem Elicitation Tech-
nique scale concerned activities that participants believed were
compromised by impaired leg function. In the treatment group,
four out of fifteen participants reported they could perform more
activities, whilst one reported a decrease in capacity to do so. In
the control group four out of eighteen reported a decrease and
only one reported an increase in the ability to perform activities.
However, no statistically significant change was found.
Based on the “global assessment” the training group showed sig-
nificant improvement compared with controls in the responses to
the questions: “How were your complaints last week” and “I am
less hindered in daily activities because of my strength reduction.
Sixty-four per cent of the training group felt they had derived ben-
efit from the intervention.
With respect to strength, there was no significant change in knee
torque or endurance although a small non-significant training ef-
fect was observed in individuals in the training group who had
higher baseline strength. This is thought to be due to a higher
potential for strength increase in the stronger individuals. The
training group also increased in strength endurance compared to
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a decrease in the control group. However, these differences were
non-significant.
Only one participant experienced adverse effects in the form of
muscle pain and transient strength reduction. The authors suggest
that as no adverse effects were observed as a result of the training,
a more intense workload should be investigated in a similar pop-
ulation in future studies.
Peripheral neuropathy
Exercise and strength training
Strength training was evaluated in participants with Charcot-
Marie-Tooth disease (Types 1 or 2) in conjunction with the ex-
ercise programme for people with myotonic dystrophy described
previously (Lindeman 1995). Thirty participants were individu-
allymatched based onmuscle strength and performance on a stair-
climbing test. Within each matched pair, participants were ran-
domly assigned to a training or control group. Outcome measures
and the training group’s intervention were identical to those out-
lined above for Lindeman 1995.
Compliance with therapy was high and a low dropout rate was
observed. Of the 30 participants randomised, 26 were analysed.
• Six-metre walk time decreased significantly in the training
group compared to the control group (P = 0.01).
• With respect to functional abilities on the WOMAC,
significant changes were found in stair climbing, rising from a
chair, getting into and out of a car, putting on socks and lying
down on the bed.
• From the Problem Elicitation Technique, in the treatment
group 7 out of 15 participants could perform more activities as a
result of training, whereas two reported a decrease in capacity to
do so. In the control group 2 out of 13 participants reported a
decrease in activities, and none reported an increase.
• No significant changes were found in the ”global
assessment“. However, 93% of the participants felt they had
derived benefit from the intervention.
• Isokinetic knee extension torque increased significantly in
the training group (14%, P < 0.005) and flexion torque
increased but without statistical significance (13%, P = 0.07).
Two participants experienced adverse effects in the form of muscle
pain and transient strength reduction. The authors suggest that as
minimal adverse effects were observed as a result of the training, a
more intense workload could be investigated in a similar popula-
tion in future studies.
Night splinting
The effects of wearing pre-formed ankle splints at night were eval-
uated in a randomised crossover trial of participants with Charcot-
Marie-Tooth disease Type 1A and a restricted range of passive dor-
siflexion (Refshauge 2006). The splints were fitted and adjusted
into dorsiflexion by the treating physiotherapist until participants
felt a tolerable stretch in their calf muscles. Participants were in-
structed to wear the splint all night and to remove it only to walk
short distances. At the initial assessment the treating physiother-
apist randomly selected the leg to be splinted first by tossing a
coin. After 6 weeks the splint was changed to the opposite leg and
at 12 weeks the splint was removed. A blinded assessor evaluated
participants at 6, 12 and 26 weeks for passive range of movement
(dorsiflexion and eversion) and isometric muscle strength (dorsi-
flexors, invertors and evertors). Pooling of limbs is inappropriate
as it artificially inflates sample size and therefore power. To satisfy
independence requirements for statistical analysis, only data from
the first period of the cross-over trial was included in this review, as
recommended in the Cochrane handbook (Higgins 2008). This
also eliminated any concerns of carry-over effects.
Fourteen patients (8 female) with a mean age of 15 (SD 8), were
randomised into the study. One participant dropped out during
the first 6-week period and was excluded from analysis. The re-
maining 13 participants complied well with treatment, wearing
the splints for a mean of 7 hours per night for 37 out of a pos-
sible 42 nights. Despite this, wearing night splints for 6 weeks
did not have a significant effect on passive dorsiflexion, eversion
or muscle strength around the ankle. The authors concluded that
wearing night splints does not increase ankle range of movement
or strength in people with Charcot-Marie-Tooth disease Type 1A.
Risk of bias in included studies
Details of the methodological quality of the included studies are
described in the ’Characteristics of included studies, and Table 2.
All studies were rated using the van Tulder (van Tulder 1997) scale
of methodological quality. Studies were included if they fulfilled
the criteria specified above.
Manzur 1992
Details of randomisation were not explicit stating only that partic-
ipants were randomised into groups. No details of allocation con-
cealment were provided. In addition blinding of outcome asses-
sors was not carried out. However, withdrawal and dropouts were
described and acceptable and follow-up measures were carried out
at short and long-term. Intention-to-treat analysis was also carried
out.
Lindeman 1995
In the Lindeman 1995 study, participants were individually
matched into pairs on the basis of muscle strength and perfor-
mance on a stair-climbing test. Within each matched pair partic-
ipants were randomly assigned to a training or control group. Al-
though treatment allocation was not concealed during randomi-
sation, assessors were blinded to treatment allocation. This was
monitored and results revealed assessors were aware of participants’
group in only 20% of cases. Withdrawal and dropouts were de-
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scribed and acceptable and follow-up measures were performed at
both short and long-term stages. Dropouts were not accounted
for in the statistical analysis therefore it can not be described as
intention-to-treat.
van der Kooi 2007, van der Kooi 2004
In van der Kooi 2007 the secondary outcome measures of a pre-
viously published study (van der Kooi 2004) are reported. In the
study participants were randomly assigned either to a ”training“ or
”non-training“ group and again into a drug treatment or placebo
group. No further details on the randomisation methods were pro-
vided and there was no evidence of allocation concealment. Par-
ticipants and therapists and clinical evaluators were blinded to the
drug treatment. Clinical evaluators were also blinded to training
allocation, with the exception of the one repetition maximum.
This specific measurement was carried out by an unblinded phys-
iotherapist as it carried too great a risk of unblinding the clinical
evaluator. Withdrawals and dropouts were described and accept-
able. Short-term and long-term follow up measures were collected
and an intention-to treat analysis was performed.
Refshauge 2006
The study was not truly randomised as the participants’ contralat-
eral legs formed the control group. In addition, the treating phys-
iotherapist performed the randomisation procedure so allocation
was not concealed. Baseline scores of flexibility and strength ap-
pear matched between groups but statistical differences were not
given. Blinding of participants and care providers was not pos-
sible but blinding of outcome assessors was ensured. Retention
and adherence rates were described and acceptable, and short- and
long-term follow-upmeasures were taken. Adverse events were not
documented as such, however the authors did report one dropout
on the grounds of discomfort. This participant was not included
in the statistical analysis so the study was not analysed on an in-
tention-to treat basis.
Effects of interventions
Duchenne muscular dystrophy
Primary outcome measure: Walking ability using a validated
objective test
In the Manzur 1992 study (n = 20), ”early“ surgery did not have a
significant effect on 28 foot or 150 foot walking times at one-year
follow-up. The 28 foot walking time deteriorated (increased time)
by a mean of 0.1 seconds in both the control and intervention
group (MD 0.00 seconds, 95% confidence interval (CI) -0.83 to
0.83, seeAnalysis 1.1). The 150 footwalking time also deteriorated
(increased time) by a mean of 1.22 seconds in the control group
and 4.1 seconds in the intervention group (MD -2.88, favouring
the control group, 95% CI -8.18 to 2.42, see Analysis 1.2). At
the two-year follow-up data for 150 foot walking times were only
available for five control and six surgery participants. Three of
the six operated boys deteriorated rapidly in the second year post
surgery. The data were not available at the nine-year follow up
stage.
Secondary outcome measures: ankle ROM, ankle
dorsiflexor strength, activity/participation measures, QOL
and adverse effects
In the same study, early surgery did not have a significant effect
on muscle strength measured by mean kg force of six lower limb
muscle groups (MD 0.00 kg force, 95% CI -0.55 to 0.55, see
Analysis 1.4). Both groups had deteriorated by 0.7 kg at 12months
follow-up. Motor ability score decreased by a mean of two out of
40 in the surgery group compared to one out of 40 in the control
group (MD -1.00, favouring the control group, 95% CI -3.08 to
1.08, see Analysis 1.3). Surgery appeared to have a positive effect
on Achilles tendon contractures in the short-term, with a mean
increase of 3º in the control group compared to a mean decrease
of 7.5º in the surgery group. At two years, five of six operated
boys had recurrence of contracture and all (number not given) had
recurrence at nine years (Manzur 1992).
Facioscapulohumeral muscular dystrophy
Primary outcome measure: Walking ability using a validated
objective test
Data for this outcome were not available.
Secondary outcome measures: ankle ROM, ankle
dorsiflexor strength, activity/participation measures, QOL
and adverse effects
In the van der Kooi 2004 trial, with a total of 65 participants, there
was a mean decrease in isometric dorsiflexor strength at the ankle
of 1.13 kg in the control group and a mean decrease of 1.56 kg
in the training group. There was no significant difference between
the two groups (MD -0.43 kg, favouring the control group, 95%
CI -2.49 to 1.63, see Analysis 2.1). Dynamic strength decreased
by a mean of 1.5 kg and 1.06 kg in the control and training
groups respectively (MD 0.44 kg, favouring the training group,
95% CI -0.89 to 1.77, see Analysis 2.2). There was an increase
in the strength of the other exercised muscle group, elbow flexors,
but that was not the topic of this review.
In the same trial moderate intensity strength training did not lead
to any significant changes in pain, fatigue, functional status or
psychological distress (van der Kooi 2007). The mean differences
(95%CI) between training and non-training groups for the Visual
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Analogue Scale (VAS) (main pain measure), Checklist Individ-
ual Strength (CIS) (main fatigue measure), Sickness Impact Pro-
file (SIP) (functional status), Symptom Checklist-90 (SCL) and
Beck Depression Inventory for primary care (BDI) (psychological
distress) were as follows; VAS -2.30, favouring the control group
(-11.16 to 6.56), CIS -3.00, favouring the control group (-8.00
to 2.00), SIP -62.00, favouring the control group (-228.99 to
104.99), SCL -2.00,favouring the control group (-10.51 to 6.51)
and BDI -0.60, favouring the control group (-1.66 to 0.46), see
Analysis 2.3, Analysis 2.4, Analysis 2.5, Analysis 2.6 to Analysis
2.7.
Myotonic dystrophy
Primary outcome measure: Walking ability using a validated
objective test
In the Lindeman 1995 study, there was no significant change in
mean walking time over six or 50 metres following a 24-week
strength training programme. The mean improvement (decrease
in time) was 0.5 and 3.5 seconds respectively in the control group
and 0.3 and 2.7 seconds in the training group. For the six-metre
walk, the MD between groups was -0.20 seconds, favouring the
control group, 95% CI -0.79 to 0.39 (see Analysis 3.1) and for the
50 metre walk the MD was -0.80 seconds, favouring the control
group, 95% CI -5.29 to 3.69 (see Analysis 3.2).
Secondary outcome measures: ankle ROM, ankle
dorsiflexor strength, activity/participation measures, QOL
and adverse effects
The same study demonstrated no significant change in time taken
(in seconds) for descending stairs, climbing stairs, rising from a
chair or standing from lying supine (see Analysis 3.3). There was
statistically significant improvement in self-report of ease of stand-
ing, getting into and out of a car and putting on socks, but the
numerical results were not provided. No serious side effects of
training occurred however one patient dropped out, on the advice
of their general practitioner, due to back complaints.
Charcot-Marie-Tooth disease
Primary outcome measure: Walking ability using a validated
objective test
In the Lindeman 1995 study, the mean six metre walking time
improved (decreased) significantly following a 24-week strength-
training programme. The walking time decreased by 1 second in
the training group and 0.3 seconds in the control group (MD
0.70 seconds, favouring the training group, 95% CI 0.23 to 1.17,
see Analysis 4.1). A significant difference was not seen in the 50
metre timed walk. The training group decreased by a mean of 2.2
seconds and the control group decreased by a mean of 0.3 seconds
(MD 1.9 seconds, favouring the training group, 95% CI -0.29 to
4.09, see Analysis 4.2).
Secondary outcome measures: ankle ROM, ankle
dorsiflexor strength, activity/participation measures, QOL
and adverse effects
The trainingprogramme in the Lindeman 1995 study led tono sig-
nificant change in time taken for descending stairs, climbing stairs,
rising from a chair or standing from lying supine (see Analysis
4.3). There was a significant improvement in self reported stair
climbing, rising from a chair, getting into and out of a car, putting
on socks and lying down on the bed, but numerical results were
not provided.
Night splinting for six weeks had no significant effect on passive
ankle range of movement or strength (Refshauge 2006). Mean
dorsiflexion increased by 3 degrees in both the night splinting and
control groups immediately after the intervention period (MD
0.00 degrees, 95% CI -5.13 to 5.13, see Analysis 5.1). Mean ever-
sion increased by 1 degree in both the night splinting and control
groups (MD 0.00 degree, 95% CI -1.96 to 1.96, see Analysis 5.2).
Mean dorsiflexion force increased by 20 N and 1 N in the inter-
vention and control groups respectively (mean difference 19.00N,
favouring night splinting, 95% CI -60.14 to 98.14, see Analysis
5.3), mean eversion increased by 0 N in the intervention group
and 5 N in the control group (mean difference -5.00 N, favouring
the control group, 95% CI -138.18 to 128.18, see Analysis 5.4),
and mean inversion increased by 95 N in the intervention group
and 93 N in the control group (mean difference 2.00 N, favouring
night splinting, 95% CI -124.00 to 128.00, see Analysis 5.5).
Subgroup analysis
Insufficient data were available to allow us to compare interven-
tions in the common aetiological subgroups proposed in the pro-
tocol.
D I S C U S S I O N
The review update provides little evidence to support any inter-
vention for treating foot drop in terms of improving walking or
secondary outcomes. The differences in patient condition and
outcomemeasures between studies made meta-analysis impossible
and made it difficult to present firm conclusions from the review.
In addition, many of the studies examined were excluded due to
insufficient methodological quality, which substantially reduced
the body of evidence.
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Duchenne muscular dystrophy
There is some evidence that early surgery intervention is not ef-
fective in people with Duchenne muscular dystrophy in terms of
walking speed, muscle strength or other measures of functional
’motor ability’ at one, two or nine years after surgery. Surgery ap-
peared to have a positive effect on contractures in the short-term
although no long-term advantage was observed (Manzur 1992).
The long-term risk of surgery increasing disability has not been
assessed.
Facioscapulohumeral muscular dystrophy
A six-week strength training programme of the ankle flexors failed
to have a significant effect on strength in participants with fa-
cioscapulohumeral muscular dystrophy (van der Kooi 2004). The
training programme also failed to have a significant effect on either
activity and participation levels as measured by the Sickness Im-
pact Profile, and dimensions of quality of life including pain, fa-
tigue and psychological distress (van der Kooi 2007). The strength
training intervention was well tolerated with no reported adverse
events.
Myotonic dystrophy
A 24-week strength-training programme was found to have no
effect on walking speed or time taken to complete functional tasks
(Lindeman 1995). Participants reported more ease with standing,
getting into and out of a car and putting on socks, but numerical
data were not presented.
Charcot-Marie-Tooth disease
A 24-week strength training programme was found to improve
walking speed but led to no significant change in time taken for
climbing stairs, descending stairs, rising from a chair or standing
from lying supine (Lindeman 1995). Participants reported im-
provement in functional tasks such as rising from a chair, getting
into and out of a car, putting on socks and lying down on the bed,
but numerical data were not presented.
Night splinting, holding the ankle in maximum dorsiflexion for
six weeks, did not lead to any significant improvement in mus-
cle strength or passive range of movement around the ankle
(Refshauge 2006). One participant out of 14 reported discomfort
from wearing the splint.
Excluded studies
Most of the studies were excluded because of methodological inad-
equacies, for example lack of randomisation or drop outs exceed-
ing 40%, and/or did not use outcome measures specified in the
review. A non-randomised study (without masked assessment) by
Forst 1999 described the long-term outcome of 213 participants
with Duchenne muscular dystrophy 87 of whom had surgery.
They concluded that the operation delayed the loss of indepen-
dent ambulation by 1.25 years, and change in strength did not
differ between groups. However, the baseline characteristics of the
two groups were not reported. In a randomised study of 27 boys
with Duchenne muscular dystrophy Hyde 2000 investigated the
effects of wearing night splints on contractures and concluded that
the treatment group had a statistically significant annual delay of
23% in the development of contractures compared to the control
group. However, the study was categorised as flawed because the
number of dropouts was excessive (9 of 15, 60% in the interven-
tion group). The effect of an ankle-foot orthosis on the strength
of paretic dorsiflexors was investigated in a non-randomised study
of 26 people with foot drop secondary to peroneal neuropathy
or L5 radiculopathy of six weeks to twelve months duration by
Geboers 2001a. The authors concluded that ankle-foot-orthosis
did not influence the restoration of strength in participants with
recent peripheral paralysis and, did not adversely influence recov-
ery. Additionally, the authors stated that the decrease in strength
observed in the healthy side of participants might be attributable
to an overall loss of strength due to a decrease in activity.
This review covered participants of all ages, described as having
lower motor neuron or floppy foot drop or contractures of ten-
dons that develop secondary to foot drop. The wide range of pa-
tient characteristics, incomparable outcome measures and poor
methodological quality made it difficult to carry out any meta-
analysis which in turn made it difficult to draw hard conclusions
from the review. Exercise intervention is well tolerated andwithout
adverse effects and may have a positive effect particularly in those
with Charcot-Marie-Tooth disease. However strong evidence is
lacking and further studies to support these findings would be
beneficial. Early surgery was also shown to have few benefits for
children with Duchenne muscular dystrophy but the long-term
risks have not been assessed.
Limitations of this review
This review is subject to various limitations. First, our search may
have missed some relevant studies. The terms we used to identify
the groups of participants are imprecise and it is possible that
studies may have been undertaken and reported using other terms
or simply giving the underlying disease (e.g. poliomyelitis), on the
grounds that there would be no clinical need to specify that there
was a floppy foot drop. Nevertheless, searching for studies through
the treatment given (e.g. orthoses) would have identified many of
these studies.
Second, the review was based on the assumption that rehabil-
itation treatments for foot drop resulting from reduced muscle
strength and no increase in muscle tone could be considered as
being similar in their effects and side effects.However this may not
11Rehabilitation interventions for foot drop in neuromuscular disease (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
be the case. For example it is possible that muscle strengthening
exercises could be beneficial in people with disease of the lower
motor neuron but harmful in people with disease of the muscle
itself. In fact the evidence would suggest that this is not the case,
but there may be other examples where there is a differential ef-
fect. This review excluded studies where foot drop resulted from
upper motor neuron disorders (e.g. stroke) and non-pathological
nerve damage (e.g. laceration, crush injury, ischemia, mechanical
irritation, compression, traction). Still, it is important to consider
that the aetiology of foot drop may differ between different lower
motor neuron conditions alone. For example, in conditions such
as diabetes and hereditary sensory motor neuropathy, foot drop
may be a result of proprioceptive impairments as well as motor
neuropathy itself. Responsiveness to treatment may therefore vary.
Third, the choice of primary outcome measure (quantitative mea-
sures of walking performance) was based on the assumption that
walking speed would correlate with performance in most other ac-
tivities involving mobility. The results in at least one of the studies
suggest that this may not be true, and that it may not be sensible in
future to focus on walking speed. The alternative is to investigate
a range of specific activities that depend upon aspects of mobility.
Scales such as the Rivermead mobility index will be considered in
future updates.
There is empirical evidence that the use of scales, which use a
scoring system to assess quality of studies, give variable results.
Therefore, in line with the latest Cochrane guidelines, future up-
dates of this review will assess risk of bias using methods set out
in Chapter 8 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2008) .
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence from one trial suggests that strengthening exercises are
not detrimental andmay benefit the ability towalk in patients with
Charcot-Marie-Tooth disease. However, limited evidence suggests
that strength training is not effective at improving walking ability
in patientswithmyotonic dystrophy, andnot effective at increasing
ankle strength in patients with facioscapulohumeral muscular dys-
trophy. Results from one trial suggests that wearing night splints
for six weeks has no effect on range of movement or strength of the
ankle in people with Charcot-Marie-Tooth disease, and data from
another trial suggest that early surgery to lengthen the Achilles
tendon in Duchenne muscular dystrophy has no significant ben-
efit on walking ability after one, two or nine years.
Implications for research
More evidence is needed to prove/disprove rehabilitation effects
aimed at foot drop in patients with neuromuscular diseases at the
level of the lower motor neuron. Exercise regimens of varying in-
tensity and frequency have provided some evidence of benefit and
should be evaluated in more detail in the future. The use of or-
thotics on function and physiological cost would be worthy of
more investigation. Future studies should include outcome mea-
sures which assess aspects such as activities of daily living and gait,
not just outcomes aimed at the impairment level of disability, e.g.
strength and range of motion. It is important to link changes in
strength and range of motion with actual levels of activity and
participation, which are more meaningful in clinical practice and
would allow readers to assess the influence of interventions on ev-
ery day life.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Lindeman 1995
Methods RCT of matched pairs (matching on muscle strength).
Participants Participants with myotonic dystrophy (myD) or Charcot-Marie-Tooth disease (CMT)
Interventions Exercise versus no exercise.
14 of 18 randomised matched MyD pairs analysed at 24 weeks.
13 of 15 randomised matched CMT pairs analysed at 24 weeks.
Outcomes Muscle strength and endurance, walking, stairs, WOMAC, SIP, VAS (life activities)
Notes Statistical change only in walking in CMT: trends to positive effect in all parameters
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Manzur 1992
Methods Unblinded RCT.
Participants Boys aged 4 to 6 years with Duchenne muscular dystrophy.
Interventions Surgical (n = 10) versus conservative treatment (n = 10).
Outcomes Muscle strength, walking, Gower’s time, contracture measurement, motor activities
Notes No difference in outcome at 1 year.
Follow up study in 1999, No difference in outcome at 8 to 11 years
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Refshauge 2006
Methods Randomised, crossover trial with repeated measures.
Participants Individuals with genetically confirmed Charcot-Marie-Tooth disease Type 1A and less than or equal to
15 degrees dorsiflexion
Interventions Night splint worn for 6 weeks (n = 14 legs) versus no splint (n = 14 legs)
One drop-out due to splint discomfort before 3/52 - excluded from analysis (13 legs analysed in each
group)
Outcomes Range of motion (dorsiflexion and eversion) and muscle strength (dorsiflexion, eversion and inversion)
Notes Night splinting did not have a significant effect on any of the outcomes measured
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
van der Kooi 2004
Methods Unblinded RCT (two stage).
Participants Participants with facioscapulohumeral muscular dystrophy.
Interventions Strength training (n = 34) versus no training (n = 31): second randomisation at 26/52 into albuterol vs
no drug treatment
Outcomes Muscle strength in legs and arms and muscle mass at 6 weeks.
Muscle strength in legs and arms at 1 year.
Notes At 6 weeks, training led to increased strength: statistically significant only at elbow
At 1 year, training led to increased dynamic of elbow; albuterol increased elbow flexion: ankle dorsiflexion
deteriorated .
Published abstracts of both parts of the study van der Kooi 2000 and van der Kooi 2001
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
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van der Kooi 2007
Methods Unblinded RCT (two stage).
Participants Participants with a clinical diagnosis of facioscapulohumeral muscular dystrophy
Interventions Randomisation at baseline into strength training (n =34) versus no training (n=31). Second randomisation
at 26/52 into albuterol versus no drug treatment
Outcomes Self-reported pain (MPQ and DOP), fatigue (CIS, DOF and DOA), functional status (SIP) and psycho-
logical distress (SCL and BDI-PC)
Notes Neither strength training nor albuterol had a clear positive or negative effect on pain, fatigue, functional
status or psychological distress
One patient stopped training and four discontinued medication due to side effects
Each participant had to complete 6 questionnaires at the baseline and final visit. Only 19/780 question-
naires were not handed in
Primary outcomes reported previously (van der Kooi 2004).
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
RCT - randomised controlled trial
WOMAC - Western Ontario and McMaster University Osteoarthritis Index
SIP - Sickness Impact Profile
VAS - Visual analogue scale
MPQ - McGill Pain Questionnaire
DOP - daily observed pain score
CIS - Checklist individual strength
DOF - daily observed fatigue
DOA - daily observed activity
SIP - sickness impact profile
SCL - symptom checklist-90
BDI-PC - Beck depression index - Primary care
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Brumett 2005 Not a RCT (series of case studies), 3 participants with probable upper rather than lower motor neuron weakness
and 2 participants with unclear diagnosis
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(Continued)
Farmer 2006 Not a RCT (all participants completed 10 m walk under 3 different conditions). The 9 participants did not share
common diagnosis. Possible contamination of results due to participant familiarity with orthoses being tested
Forst 1995 Not randomised, compared with ’natural history’ cohort.
Forst 1999 Not randomised, compared with ’natural history’ cohort.
Geboers 2001a Not randomised, if alternative allocation on enrolment was used there would not be a 4 person difference between
groups at entry (11,15). Assessment not masked. No allocation concealment. Large between group difference in
mean age at entry (42 versus 60 years)
Geboers 2001b Same as Geboers 2001a and Geboers 2002.
Geboers 2002 Same study as 2001a, compliance not reported for follow up data
Hove 1998 Not a RCT (case series design).
Hyde 2000 Drop out rate, 9 of 15 in intervention, 7 of 12 in ’control’, total 16 of 27
Matjaic 2006 Balance intervention not targeted at foot drop.
McDonald 2005 Not a RCT (epidemiological case-control).
Olsen 2005 Not a RCT (case series). All of the participants had upper limb and facial weakness but only half had lower limb
weakness
Richardson 2001 Did not use the specified outcome measures. Foot drop not diagnosed, paper talks about ’subclinical motor
involvement’
Vigasio 2008 Not a RCT (case series design).
Wiesinger 1998 Not foot drop.
RCT - randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Early surgery versus control in Duchenne muscular dystrophy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in 28 ft walking time
(seconds)
1 20 Mean Difference (IV, Fixed, 95% CI) Not estimable
2 Change in 150 ft walking time
(seconds)
1 20 Mean Difference (IV, Fixed, 95% CI) -2.88 [-8.18, 2.42]
3 Change in motor ability score
(max 40)
1 20 Mean Difference (IV, Fixed, 95% CI) -1.0 [-3.08, 1.08]
4 Change in combined strength
of 6 lower limb muscle groups
(kg)
1 20 Mean Difference (IV, Fixed, 95% CI) Not estimable
Comparison 2. Strength training versus control in FSHD
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in muscle strength of
ankle dorsiflexors - maximum
voluntary isometric contraction
(kg)
1 65 Mean Difference (IV, Fixed, 95% CI) -0.43 [-2.49, 1.63]
2 Change in muscle strength ankle
dorsiflexors - dynamic strength
(kg)
1 65 Mean Difference (IV, Fixed, 95% CI) 0.44 [-0.89, 1.77]
3 Change in visual analogue scale -
pain (min 0, max 100)
1 65 Mean Difference (Fixed, 95% CI) -2.3 [-11.16, 6.56]
4 Change in Checklist Individual
Strength - Fatigue (min 0, max
120)
1 65 Mean Difference (Fixed, 95% CI) -3.0 [-6.00, 2.00]
5 Change in health related
function - Sickness Impact
Profile (min 0, max 10,289)
1 65 Mean Difference (Fixed, 95% CI) -60.00 [-228.99,
104.99]
6 Change in psychological distress
- Symptom Cheklist-90 (min
90, max 450)
1 65 Mean Difference (Fixed, 95% CI) -2.0 [-10.51, 6.51]
7 Change in psychological distress
- Beck Depression Inventory
for primary care (min 0, max
21)
1 65 Mean Difference (Fixed, 95% CI) -0.6 [-1.66, 0.46]
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Comparison 3. Strength training versus control in myotonic dystrophy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in time to walk 6 m at a
comfortable pace (seconds)
1 28 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.79, 0.39]
2 Change in time to walk 50 m at
a fast pace (seconds)
1 28 Mean Difference (IV, Fixed, 95% CI) -0.80 [-5.29, 3.69]
3 Change in time spent to achieve
mobility activities in seconds
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Descending stairs 1 28 Mean Difference (IV, Fixed, 95% CI) 2.0 [-2.22, 6.22]
3.2 Climbing stairs 1 28 Mean Difference (IV, Fixed, 95% CI) 0.8 [-2.38, 3.98]
3.3 Standing up from a chair 1 28 Mean Difference (IV, Fixed, 95% CI) 1.0 [-1.14, 3.14]
3.4 Standing up from lying
supine
1 28 Mean Difference (IV, Fixed, 95% CI) -0.9 [-2.27, 0.47]
Comparison 4. Strength training versus control in Charcot-Marie-Tooth disease
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in time to walk 6 m at a
comfortable pace (seconds)
1 26 Mean Difference (IV, Fixed, 95% CI) 0.7 [0.23, 1.17]
2 Change in time to walk 50 m at
a fast pace (seconds)
1 26 Mean Difference (IV, Fixed, 95% CI) 1.90 [-0.29, 4.09]
3 Change in time spent to achieve
mobility activities (seconds)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Descending stairs 1 26 Mean Difference (IV, Fixed, 95% CI) 0.79 [-0.37, 1.95]
3.2 Climbing stairs 1 26 Mean Difference (IV, Fixed, 95% CI) 0.71 [-0.29, 1.71]
3.3 Standing up from a chair
(seconds)
1 26 Mean Difference (IV, Fixed, 95% CI) 0.15 [-0.17, 0.47]
3.4 standing up from lying
supine (seconds)
1 26 Mean Difference (IV, Fixed, 95% CI) 0.2 [-0.22, 0.62]
Comparison 5. Night splinting versus control in Charcot-Marie-Tooth disease
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in dorsiflexion range of
motion (deg)
1 26 Mean Difference (IV, Fixed, 95% CI) Not estimable
2 Change in eversion range of
motion (deg)
1 26 Mean Difference (IV, Fixed, 95% CI) Not estimable
3 Change in dorsiflexion force (N) 1 26 Mean Difference (IV, Fixed, 95% CI) 19.0 [-60.14, 98.14]
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4 Change in eversion force (N) 1 26 Mean Difference (IV, Fixed, 95% CI) -5.0 [-138.18, 128.
18]
5 Change in inversion force (N) 1 26 Mean Difference (IV, Fixed, 95% CI) 2.0 [-124.00, 128.
00]
Analysis 1.1. Comparison 1 Early surgery versus control in Duchenne muscular dystrophy, Outcome 1
Change in 28 ft walking time (seconds).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 1 Early surgery versus control in Duchenne muscular dystrophy
Outcome: 1 Change in 28 ft walking time (seconds)
Study or subgroup Surgery Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Manzur 1992 10 -0.1 (0.95) 10 -0.1 (0.95) 100.0 % 0.0 [ -0.83, 0.83 ]
Total (95% CI) 10 10 100.0 % 0.0 [ -0.83, 0.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours control Favours surgery
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Analysis 1.2. Comparison 1 Early surgery versus control in Duchenne muscular dystrophy, Outcome 2
Change in 150 ft walking time (seconds).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 1 Early surgery versus control in Duchenne muscular dystrophy
Outcome: 2 Change in 150 ft walking time (seconds)
Study or subgroup Surgery Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Manzur 1992 10 -4.1 (6.64) 10 -1.22 (5.38) 100.0 % -2.88 [ -8.18, 2.42 ]
Total (95% CI) 10 10 100.0 % -2.88 [ -8.18, 2.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours control Favours surgery
Analysis 1.3. Comparison 1 Early surgery versus control in Duchenne muscular dystrophy, Outcome 3
Change in motor ability score (max 40).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 1 Early surgery versus control in Duchenne muscular dystrophy
Outcome: 3 Change in motor ability score (max 40)
Study or subgroup Surgery Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Manzur 1992 10 -2 (2.21) 10 -1 (2.53) 100.0 % -1.00 [ -3.08, 1.08 ]
Total (95% CI) 10 10 100.0 % -1.00 [ -3.08, 1.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours control Favours surgery
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Analysis 1.4. Comparison 1 Early surgery versus control in Duchenne muscular dystrophy, Outcome 4
Change in combined strength of 6 lower limb muscle groups (kg).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 1 Early surgery versus control in Duchenne muscular dystrophy
Outcome: 4 Change in combined strength of 6 lower limb muscle groups (kg)
Study or subgroup Surgery Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Manzur 1992 10 -0.7 (0.63) 10 -0.7 (0.63) 100.0 % 0.0 [ -0.55, 0.55 ]
Total (95% CI) 10 10 100.0 % 0.0 [ -0.55, 0.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours control Favours surgery
Analysis 2.1. Comparison 2 Strength training versus control in FSHD, Outcome 1 Change in muscle
strength of ankle dorsiflexors - maximum voluntary isometric contraction (kg).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 2 Strength training versus control in FSHD
Outcome: 1 Change in muscle strength of ankle dorsiflexors - maximum voluntary isometric contraction (kg)
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
van der Kooi 2004 34 -1.56 (4.16) 31 -1.13 (4.28) 100.0 % -0.43 [ -2.49, 1.63 ]
Total (95% CI) 34 31 100.0 % -0.43 [ -2.49, 1.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours control Favours training
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Analysis 2.2. Comparison 2 Strength training versus control in FSHD, Outcome 2 Change in muscle
strength ankle dorsiflexors - dynamic strength (kg).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 2 Strength training versus control in FSHD
Outcome: 2 Change in muscle strength ankle dorsiflexors - dynamic strength (kg)
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
van der Kooi 2004 34 -1.06 (2.78) 31 -1.5 (2.68) 100.0 % 0.44 [ -0.89, 1.77 ]
Total (95% CI) 34 31 100.0 % 0.44 [ -0.89, 1.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours control Favours training
Analysis 2.3. Comparison 2 Strength training versus control in FSHD, Outcome 3 Change in visual analogue
scale - pain (min 0, max 100).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 2 Strength training versus control in FSHD
Outcome: 3 Change in visual analogue scale - pain (min 0, max 100)
Study or subgroup Training Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
van der Kooi 2007 34 31 -2.3 (4.52) 100.0 % -2.30 [ -11.16, 6.56 ]
Total (95% CI) 100.0 % -2.30 [ -11.16, 6.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours control Favours training
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Analysis 2.4. Comparison 2 Strength training versus control in FSHD, Outcome 4 Change in Checklist
Individual Strength - Fatigue (min 0, max 120).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 2 Strength training versus control in FSHD
Outcome: 4 Change in Checklist Individual Strength - Fatigue (min 0, max 120)
Study or subgroup Training Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
van der Kooi 2007 34 31 -3 (2.55) 100.0 % -3.00 [ -8.00, 2.00 ]
Total (95% CI) 100.0 % -3.00 [ -8.00, 2.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours control Favours training
Analysis 2.5. Comparison 2 Strength training versus control in FSHD, Outcome 5 Change in health related
function - Sickness Impact Profile (min 0, max 10,289).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 2 Strength training versus control in FSHD
Outcome: 5 Change in health related function - Sickness Impact Profile (min 0, max 10,289)
Study or subgroup Training Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
van der Kooi 2007 34 31 -62 (85.2) 100.0 % -62.00 [ -228.99, 104.99 ]
Total (95% CI) 100.0 % -62.00 [ -228.99, 104.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Strength training versus control in FSHD, Outcome 6 Change in psychological
distress - Symptom Cheklist-90 (min 90, max 450).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 2 Strength training versus control in FSHD
Outcome: 6 Change in psychological distress - Symptom Cheklist-90 (min 90, max 450)
Study or subgroup Training Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
van der Kooi 2007 34 31 -2 (4.34) 100.0 % -2.00 [ -10.51, 6.51 ]
Total (95% CI) 100.0 % -2.00 [ -10.51, 6.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Strength training versus control in FSHD, Outcome 7 Change in psychological
distress - Beck Depression Inventory for primary care (min 0, max 21).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 2 Strength training versus control in FSHD
Outcome: 7 Change in psychological distress - Beck Depression Inventory for primary care (min 0, max 21)
Study or subgroup Training Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
van der Kooi 2007 34 31 -0.6 (0.54) 100.0 % -0.60 [ -1.66, 0.46 ]
Total (95% CI) 100.0 % -0.60 [ -1.66, 0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Strength training versus control in myotonic dystrophy, Outcome 1 Change in
time to walk 6 m at a comfortable pace (seconds).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 3 Strength training versus control in myotonic dystrophy
Outcome: 1 Change in time to walk 6 m at a comfortable pace (seconds)
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lindeman 1995 14 0.3 (0.8) 14 0.5 (0.8) 100.0 % -0.20 [ -0.79, 0.39 ]
Total (95% CI) 14 14 100.0 % -0.20 [ -0.79, 0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Strength training versus control in myotonic dystrophy, Outcome 2 Change in
time to walk 50 m at a fast pace (seconds).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 3 Strength training versus control in myotonic dystrophy
Outcome: 2 Change in time to walk 50 m at a fast pace (seconds)
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lindeman 1995 14 2.7 (6.3) 14 3.5 (5.8) 100.0 % -0.80 [ -5.29, 3.69 ]
Total (95% CI) 14 14 100.0 % -0.80 [ -5.29, 3.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours control Favours training
27Rehabilitation interventions for foot drop in neuromuscular disease (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.3. Comparison 3 Strength training versus control in myotonic dystrophy, Outcome 3 Change in
time spent to achieve mobility activities in seconds.
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 3 Strength training versus control in myotonic dystrophy
Outcome: 3 Change in time spent to achieve mobility activities in seconds
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Descending stairs
Lindeman 1995 14 2.5 (7.2) 14 0.5 (3.6) 100.0 % 2.00 [ -2.22, 6.22 ]
Subtotal (95% CI) 14 14 100.0 % 2.00 [ -2.22, 6.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
2 Climbing stairs
Lindeman 1995 14 1.1 (5.8) 14 0.3 (1.8) 100.0 % 0.80 [ -2.38, 3.98 ]
Subtotal (95% CI) 14 14 100.0 % 0.80 [ -2.38, 3.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
3 Standing up from a chair
Lindeman 1995 14 1.2 (4) 14 0.2 (0.8) 100.0 % 1.00 [ -1.14, 3.14 ]
Subtotal (95% CI) 14 14 100.0 % 1.00 [ -1.14, 3.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
4 Standing up from lying supine
Lindeman 1995 14 -0.4 (1.4) 14 0.5 (2.2) 100.0 % -0.90 [ -2.27, 0.47 ]
Subtotal (95% CI) 14 14 100.0 % -0.90 [ -2.27, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Chi2 = 3.59, df = 3 (P = 0.31), I2 =17%
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Analysis 4.1. Comparison 4 Strength training versus control in Charcot-Marie-Tooth disease, Outcome 1
Change in time to walk 6 m at a comfortable pace (seconds).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 4 Strength training versus control in Charcot-Marie-Tooth disease
Outcome: 1 Change in time to walk 6 m at a comfortable pace (seconds)
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lindeman 1995 13 1 (0.5) 13 0.3 (0.7) 100.0 % 0.70 [ 0.23, 1.17 ]
Total (95% CI) 13 13 100.0 % 0.70 [ 0.23, 1.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.93 (P = 0.0033)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Strength training versus control in Charcot-Marie-Tooth disease, Outcome 2
Change in time to walk 50 m at a fast pace (seconds).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 4 Strength training versus control in Charcot-Marie-Tooth disease
Outcome: 2 Change in time to walk 50 m at a fast pace (seconds)
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lindeman 1995 13 2.2 (2.8) 13 0.3 (2.9) 100.0 % 1.90 [ -0.29, 4.09 ]
Total (95% CI) 13 13 100.0 % 1.90 [ -0.29, 4.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.089)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Strength training versus control in Charcot-Marie-Tooth disease, Outcome 3
Change in time spent to achieve mobility activities (seconds).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 4 Strength training versus control in Charcot-Marie-Tooth disease
Outcome: 3 Change in time spent to achieve mobility activities (seconds)
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Descending stairs
Lindeman 1995 13 0.7 (1.7) 13 -0.09 (1.3) 100.0 % 0.79 [ -0.37, 1.95 ]
Subtotal (95% CI) 13 13 100.0 % 0.79 [ -0.37, 1.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
2 Climbing stairs
Lindeman 1995 13 0.7 (1.4) 13 -0.01 (1.2) 100.0 % 0.71 [ -0.29, 1.71 ]
Subtotal (95% CI) 13 13 100.0 % 0.71 [ -0.29, 1.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
3 Standing up from a chair (seconds)
Lindeman 1995 13 0.2 (0.5) 13 0.05 (0.3) 100.0 % 0.15 [ -0.17, 0.47 ]
Subtotal (95% CI) 13 13 100.0 % 0.15 [ -0.17, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
4 standing up from lying supine (seconds)
Lindeman 1995 13 0.3 (0.6) 13 0.1 (0.5) 100.0 % 0.20 [ -0.22, 0.62 ]
Subtotal (95% CI) 13 13 100.0 % 0.20 [ -0.22, 0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Chi2 = 2.03, df = 3 (P = 0.57), I2 =0.0%
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Analysis 5.1. Comparison 5 Night splinting versus control in Charcot-Marie-Tooth disease, Outcome 1
Change in dorsiflexion range of motion (deg).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 5 Night splinting versus control in Charcot-Marie-Tooth disease
Outcome: 1 Change in dorsiflexion range of motion (deg)
Study or subgroup Splinting Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Refshauge 2006 13 3 (8) 13 3 (5) 100.0 % 0.0 [ -5.13, 5.13 ]
Total (95% CI) 13 13 100.0 % 0.0 [ -5.13, 5.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Night splinting versus control in Charcot-Marie-Tooth disease, Outcome 2
Change in eversion range of motion (deg).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 5 Night splinting versus control in Charcot-Marie-Tooth disease
Outcome: 2 Change in eversion range of motion (deg)
Study or subgroup Splinting Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Refshauge 2006 13 1 (3) 13 1 (2) 100.0 % 0.0 [ -1.96, 1.96 ]
Total (95% CI) 13 13 100.0 % 0.0 [ -1.96, 1.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Night splinting versus control in Charcot-Marie-Tooth disease, Outcome 3
Change in dorsiflexion force (N).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 5 Night splinting versus control in Charcot-Marie-Tooth disease
Outcome: 3 Change in dorsiflexion force (N)
Study or subgroup Splinting Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Refshauge 2006 13 20 (112) 13 1 (93) 100.0 % 19.00 [ -60.14, 98.14 ]
Total (95% CI) 13 13 100.0 % 19.00 [ -60.14, 98.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Night splinting versus control in Charcot-Marie-Tooth disease, Outcome 4
Change in eversion force (N).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 5 Night splinting versus control in Charcot-Marie-Tooth disease
Outcome: 4 Change in eversion force (N)
Study or subgroup Splinting Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Refshauge 2006 13 0 (182) 13 5 (164) 100.0 % -5.00 [ -138.18, 128.18 ]
Total (95% CI) 13 13 100.0 % -5.00 [ -138.18, 128.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours splinting
32Rehabilitation interventions for foot drop in neuromuscular disease (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.5. Comparison 5 Night splinting versus control in Charcot-Marie-Tooth disease, Outcome 5
Change in inversion force (N).
Review: Rehabilitation interventions for foot drop in neuromuscular disease
Comparison: 5 Night splinting versus control in Charcot-Marie-Tooth disease
Outcome: 5 Change in inversion force (N)
Study or subgroup Splinting Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Refshauge 2006 13 95 (152) 13 93 (175) 100.0 % 2.00 [ -124.00, 128.00 ]
Total (95% CI) 13 13 100.0 % 2.00 [ -124.00, 128.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. 01 Scoring criteria using the method of van Tulder 1997
Criterion Score positive if:
Eligibility criteria specified A list of inclusion / exclusion criteria was explicitly stated
Adverse events Adverse events described?
Assessment timings Comparable between groups?
Sample size Sample size described?
Method of randomisation A random (unpredictable) assignment sequence was used.
Treatment allocation concealment Assignment was concealed from the investigators.
Similarity of baseline characteristics The study groups were comparable at baseline for the important prognostic param-
eters
Intervention and control specifically described Details were given of the programme, including disciplines involved and treatment
duration
Blinding of observers Observers were blinded regarding treatment allocation and standardised assessment
measures were used to structure the interviews. It was scored negative if only self-
reported (questionnaire) outcomes were used and no observer outcomes
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Table 1. 01 Scoring criteria using the method of van Tulder 1997 (Continued)
Co-interventions avoided or equal Co-interventions were avoided in the design of the study or were equally divided
among the intervention groups
Compliance Compliance was measured and satisfactory in all study groups
Outcome measures relevant Outcome measures reflected disability (activity) or participation as relevant to the
intervention
Withdrawal rate acceptable The number of randomised patients minus the number of patients at the main
moment of effect measurement divided by all randomised patients and multiplied
by 100, was less than 20% for short-term outcomes or less than 30% for long-term
outcomes
Short-term outcome measurement Outcomes were measured at the end of treatment (e.g. admission to discharge) or
within 6 months of the end of treatment
Long-term outcome measurement Outcomes were measured at 1 year or more.
Intention-to-treat analysis All randomised patients were included in the analysis (minus missing values), irre-
spective of non-compliance and co-interventions. If loss to follow-up was substantial
(20% or more), an intention-to-treat analysis as well as an alternative analysis, which
accounts for missing values (e.g. a worst-case analysis), should have been performed
Point estimates and measures of variability Amean or median figure was given for each important outcome parameter, together
with a measures of variability such as standard deviation, standard error of themean,
or 95% confidence intervals
Table 2. Methodological Quality assessed by the van Tulder Method
Study ID Internal validity Descriptive criteria Statistical Criteria High Quality
Manzur 1992 5 4 2 High quality for descriptive and statistical cri-
teria
Lindeman 1995 8 5 1 High quality for all criteria
van der Kooi 2004 9 6 2 High quality for all criteria
Refshauge 2006 7 4 2 High quality for all criteria
van der Kooi 2007 9 6 2 High quality for all criteria
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1 ((foot adj1 drop$3) or floppy foot or footdrop).mp. (632)
2 exp gait disorders, neurologic/ (1947)
3 (lower adj2 (motor neuron$2 or motorneuron$2 or motoneuron$2)).mp. (1537)
4 (lower or leg or foot or ankle or achilles or tendon or peroneal nerve).mp. (949337)
5 leg/ or foot/ or ankle/ or achilles tendon/ or tendon injuries/ or peroneal nerve/ or ankle injuries/ or foot injuries/ or foot deformities,
acquired/ (88574)
6 4 or 5 (949337)
7 contracture$.mp. (16348)
8 Contracture/ (5633)
9 dorsiflex$.mp. (2834)
10 or/7-9 (19074)
11 neuromuscular$ disease$.mp. (9562)
12 exp Neuromuscular Diseases/ (197826)
13 nerve compression syndromes/ (8109)
14 nerve compression syndromes.mp. (8459)
15 exp peripheral nervous system diseases/ (96798)
16 peripheral$ nervous$ system$ disease$.mp. (16791)
17 or/11-16 (198822)
18 rehabilitation$.mp. (83228)
19 activities of daily living.mp. (40560)
20 exercise/ (46247)
21 exercise.mp. (165750)
22 (physical therap$ or physiotherap$ or physical stimulation$).mp. (44423)
23 SURGERY/ or surgery.mp. (584448)
24 ORTHOTIC DEVICES/ (3772)
25 (orthotic$ or orthos$).mp. (15726)
26 (muscle training or strength training).mp. (2418)
27 Splints/ (6507)
28 splint$.mp. (12591)
29 exp REHABILITATION/ (109523)
30 or/18-29 (930578)
31 6 and 10 (5289)
32 1 or 2 or 3 or 31 (9131)
33 17 and 32 (1881)
34 30 and 33 (282)
35 randomized controlled trial.pt. (268387)
36 controlled clinical trial.pt. (78963)
37 randomized.ab. (178675)
38 placebo.ab. (111207)
39 drug therapy.fs. (1300818)
40 randomly.ab. (129674)
41 trial.ab. (185925)
42 groups.ab. (895999)
43 or/35-42 (2373361)
44 (animals not (animals and humans)).sh. (3265712)
45 43 not 44 (2011688)
46 34 and 45 (56)
47 from 46 keep 1-56 (56)
35Rehabilitation interventions for foot drop in neuromuscular disease (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 2. EMBASE search strategy
1 ((foot adj1 drop$3) or floppy foot or footdrop).tw. or peroneus nerve paralysis/ (1024)
2 exp locomotion/ or gait disorders/ (100211)
3 (lower or leg or foot or ankle or achilles or tendon or peroneal nerve).tw. (764026)
4 leg/ or foot/ or ankle/ or achilles tendon/ or tendon injury/ or peroneus nerve/ or ankle injury/ or foot injury/ or foot malformation/
(34190)
5 (lower adj2 (motor neuron$2 or motorneuron$2 or motoneuron$2)).tw. (1347)
6 contracture$.tw. (10209)
7 Contracture/ (1657)
8 dorsiflex$.tw. (2702)
9 neuromuscular$ disease$.tw. (2527)
10 exp Neuromuscular Diseases/ (67504)
11 nerve compression/ (5926)
12 nerve compression syndrome$1.tw. (151)
13 exp peripheral neuropathy/ (22618)
14 peripheral$ nervous$ system$ disease$.tw. (58)
15 rehabilitation$.tw. (56063)
16 activities of daily living.tw. (8544)
17 exercise/ (76202)
18 exercise.tw. (106666)
19 (physical therap$ or physiotherap$ or physical stimulation$).tw. (17404)
20 SURGERY/ or surgery.tw. (457184)
21 ORTHOTICS/ (944)
22 (orthotic$ or orthos$).tw. (9749)
23 (muscle training or strength training).tw. (2295)
24 Splint/ (1684)
25 splint$.tw. (4331)
26 exp REHABILITATION/ (105927)
27 or/9-14 (94389)
28 or/15-26 (730722)
29 3 or 4 (772431)
30 6 or 7 or 8 (13373)
31 29 and 30 (4132)
32 1 or 2 or 5 or 31 (105704)
33 27 and 32 (5174)
34 28 and 33 (602)
35 Randomized Controlled Trial/ (167923)
36 Clinical Trial/ (537938)
37 Multicenter Study/ (45581)
38 Controlled Study/ (2871815)
39 Crossover Procedure/ (21204)
40 Double Blind Procedure/ (72106)
41 Single Blind Procedure/ (8107)
42 exp RANDOMIZATION/ (26723)
43 Major Clinical Study/ (1282492)
44 PLACEBO/ (125715)
45 Meta Analysis/ (34998)
46 phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/ (27492)
47 (clin$ adj25 trial$).tw. (147188)
48 ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).tw. (96115)
49 placebo$.tw. (110339)
50 random$.tw. (395507)
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51 control$.tw. (1496154)
52 (meta?analys$ or systematic review$).tw. (16639)
53 (cross?over or factorial or sham? or dummy).tw. (75274)
54 ABAB design$.tw. (42)
55 or/35-54 (4584558)
56 human/ (6459907)
57 nonhuman/ (3210836)
58 56 or 57 (9146511)
59 55 not 58 (383717)
60 55 and 56 (2870172)
61 59 or 60 (3253889)
62 34 and 61 (290)
63 from 62 keep 1-290 (290)
Appendix 3. CINAHL search strategy
S50 S18 and S37 and S48 and S50
S49 S22 OR S26
S48 S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47
S47 physiotherap* or physical therap* or stimulation
S46 muscle training or strength training
S45 rehabilitation or activities of daily living or exercise therapy or splint* or orthos* or orthotic*
S44 (MH ”Foot Orthoses“)
S43 (MH ”Surgery, Operative“)
S42 (MH ”Splints“)
S41 (MH ”Therapeutic Exercise“)
S40 (MH ”Physical Therapy“)
S39 (MH ”Lower Extremity Exercises“) or (MH ”Muscle Strengthening“)
S38 (MH ”Rehabilitation+“)
S37 S32 OR S33 OR S34 OR S35 OR S36
S36 peripheral N5 nervous N5 system N5 disease*
S35 neuromuscular N5 disease*
S34 (MH ”Peripheral Nervous System Diseases+“)
S33 (MH ”Nerve Compression Syndromes“) or (MH ”Tarsal Tunnel Syndrome“)
S32 (MH ”Neuromuscular Diseases+“)
S31 S22 or S30
S30 S26 AND S29
S29 S27 OR S28
S28 Contracture* or Dorsiflexion*
S27 (MH ”Contracture“) or (MH ”Dorsiflexion“)
S26 S24 OR S25
S25 (MH ”Lower Extremity+“) or (MH ”Achilles Tendon“) or (MH ”Ankle Injuries“) or (MH ”Foot Injuries“) or (MH ”Foot
Deformities“) or (MH ”Foot Deformities, Acquired“)
S24 lower n3 extremit* or lower n3 limb or leg or foot or ankle or achilles or peroneal n5 nerve
S23 (MH ”Lower Extremity+“)
S22 S19 or S20 or S21
S21 ”gait disorder*“
S20 (MH ”Locomotion+“)
S19 foot drop* or floppy foot or footdrop
S18 S17 or S16 or S15 or S14 or S13 or S12 or S11 or S10 or S9 or S8 or S7 or S6 or S5 or S4 or S3 or S2 or S1
S17 TI random* or AB random*
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S16 ( TI (cross?over or placebo* or control* or factorial or sham? or dummy) ) or ( AB (cross?over or placebo* or control* or factorial
or sham? or dummy) )
S15 ( TI (clin* or intervention* or compar* or experiment* or preventive or therapeutic) or AB (clin* or intervention* or compar* or
experiment* or preventive or therapeutic) ) and ( TI (trial*) or AB (trial*) )
S14 ( TI (meta?analys* or systematic review*) ) or ( AB (meta?analys* or systematic review*) )
S13 ( TI (single* or doubl* or tripl* or trebl*) or AB (single* or doubl* or tripl* or trebl*) ) and ( TI (blind* or mask*) or AB (blind*
or mask*) )
S12 ABAB design*
S11 PT clinical trial or PT systematic review
S10 (MH ”Factorial Design“)
S9 (MH ”Concurrent Prospective Studies“) or (MH ”Prospective Studies“)
S8 (MH ”Meta Analysis“)
S7 (MH ”Solomon Four-Group Design“) or (MH ”Static Group Comparison“)
S6 (MH ”Quasi-Experimental Studies“)
S5 (MH ”Placebos“)
S4 (MH ”Double-Blind Studies“) or (MH ”Triple-Blind Studies“)
S3 (MH ”Clinical Trials+“)
S2 (MH ”Crossover Design“)
S1 (MH ”Random Assignment“) or (MH ”Random Sample“) or (MH ”Simple Random Sample“) or (MH ”Stratified Random
Sample“) or (MH ”Systematic Random Sample“)
Appendix 4. AMED search strategy
1 ((foot adj1 drop$3) or floppy foot or footdrop).mp. (70)
2 gait/ or locomotion/ or movement/ (5898)
3 (lower or leg or foot or ankle or achilles or tendon or peroneal nerve).mp. (23674)
4 leg/ or foot/ or ankle/ or achilles tendon/ or tendon injuries/ or peroneal nerve/ or ankle injuries/ or foot injuries/ or foot deformities,
acquired/ (7192)
5 (lower adj2 (motor neuron$2 or motorneuron$2 or motoneuron$2)).mp. (38)
6 contracture$.mp. (426)
7 Contracture/ (131)
8 dorsiflex$.mp. (883)
9 neuromuscular$ disease$.mp. (557)
10 exp Neuromuscular Disease/ (2540)
11 nerve compression syndromes/ (208)
12 nerve compression syndromes.mp. (239)
13 exp peripheral nervous system disease/ (2246)
14 peripheral$ nervous$ system$ disease$.mp. (214)
15 rehabilitation$.mp. (36193)
16 activities of daily living.mp. (4314)
17 exercise/ (6690)
18 exercise.mp. (15287)
19 (physical therap$ or physiotherap$ or physical stimulation$).mp. (14513)
20 SURGERY/ or surgery.mp. (7759)
21 ORTHOTIC DEVICES/ (1295)
22 (orthotic$ or orthos$).mp. (1926)
23 (strength training or muscle training$).mp. (687)
24 Splints/ (84)
25 splint$.mp. (469)
26 exp REHABILITATION/ (29375)
27 or/9-14 (4804)
28 or/15-26 (67207)
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29 3 or 4 (23674)
30 6 or 7 or 8 (1267)
31 29 and 30 (947)
32 1 or 2 or 5 or 31 (6786)
33 27 and 32 (137)
34 28 and 33 (51)
35 Randomized controlled trials/ (1350)
36 Random allocation/ (288)
37 Double blind method/ (388)
38 Single-Blind Method/ (1)
39 exp Clinical Trials/ (2959)
40 (clin$ adj25 trial$).tw. (4588)
41 ((singl$ or doubl$ or treb$ or trip$) adj25 (blind$ or mask$ or dummy)).tw. (1848)
42 placebos/ (504)
43 placebo$.tw. (2188)
44 random$.tw. (10213)
45 research design/ (1637)
46 Prospective Studies/ (234)
47 (cross over stud$3 or crossover stud$3).mp. (169)
48 meta analysis/ (100)
49 (meta?analys$ or systematic review$).tw. (1162)
50 control$.tw. (22842)
51 (multicenter or multicentre).tw. (598)
52 ((study or studies or design$) adj25 (factorial or prospective or intervention or crossover or cross-over or quasi-experiment$)).tw.
(7787)
53 or/35-52 (35345)
54 34 and 53 (18)
55 or/1-5 (27847)
56 (or/9-14) or nervous system disease/ (5913)
57 55 and 56 and 28 and 53 (157)
58 from 57 keep 1-157 (157)
Appendix 5. British Nursing Index
1. ((foot adj1 drop$3) or floppy foot).mp
2. mobility/
3. (lower or leg or foot or ankle or achilles or tendon or peroneal nerve).mp
4. exp foot care/ and disorders/
5. ((lower adj2 motor neuron$2) or motorneuron$2).mp
6. contracture$.mp
7. Contracture/
8. dorsiflex$.mp
9. neuromuscular$ disease$.mp
10. exp Neuromuscular system/ and disorders/
11. nerve compression syndromes/
12. nerve compression syndromes.mp
13. exp peripheral nervous system diseases/
14. peripheral$ nervous$ system$ disease$.mp.
15. rehabilitation$.mp
16. activities of daily living.mp
17. physical fitness/
18. exercise.mp
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19. (physical therap$ or physiotherap$ or physical stimulation$).tw.
20. surgery, operative/ or surgery.mp
21. orthopaedic devices/
22. orthotic$.mp
23. orthos$.mp
24. splint$.mp
25. exp REHABILITATION/
26. or/9-14
27. or/15-25
28. 3 or 4
29. 6 or 8
30. 28 and 29
31. 1 or 2 or 5 or 30
32. 26 and 31
WH A T ’ S N E W
Last assessed as up-to-date: 23 April 2009.
Date Event Description
13 May 2009 New citation required but conclusions have not changed New authors involved in update
8 May 2009 New search has been performed New studies included.
Data amended to increase consistency and aid interpreta-
tion of results (signs assigned to mean difference adjusted
accordingly so that a positive value always corresponds to
favouring the intervention rather than control
H I S T O R Y
Protocol first published: Issue 4, 2002
Review first published: Issue 2, 2007
Date Event Description
28 July 2008 Amended Converted to new review format.
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